1. Introduction
===============

Gastric cancer (GC) is one of the most common malignant types of cancer and the third leading cause of cancer-related death worldwide in the last two decades ([@b1-ijo-54-05-1511]). In many Asian countries, particularly in China, GC is the second most common type of cancer and the leading malignancy as regards the incidence and mortality rate ([@b2-ijo-54-05-1511]). Although advances in surgical techniques have improved the prognosis of patients with early-stage GC, the majority of patients are diagnosed at the advanced stages of the disease and thus have to undergo chemotherapy and radiotherapy ([@b3-ijo-54-05-1511]). However, the 5-year-survival rate has not improved significantly due to the development of chemoresistance to anti-cancer drugs ([@b4-ijo-54-05-1511]). Drug resistance, which is frequently observed in GC, threatens the success rate of chemotherapy and the survival of patients with GC. The underlying mechanisms of drug resistance remain to be fully understood ([@b5-ijo-54-05-1511]-[@b7-ijo-54-05-1511]). One well-known mechanism is the modulation of the epithelial-mesenchymal transition (EMT) process which converts epithelial cells to mesenchymal cells. Studies have confirmed that EMT can induce drug resistance by decelerating the proliferation rate of cancer cells, upregulating the expression of ATP binding cassette (ABC) transporters which mediate drug efflux, and increasing the expression of anti-apoptotic proteins ([@b8-ijo-54-05-1511]-[@b10-ijo-54-05-1511]). It has also been demonstrated that EMT can reconstruct the tumor microenvironment, thereby inducing resistance to immunotherapies ([@b11-ijo-54-05-1511]). Another well-known mechanism related to drug resistance is cancer stem cells (CSCs). CSCs are a cell population with high tumorigenic potential in tumors, and these cells modulate cancer initiation, development and metastasis ([@b12-ijo-54-05-1511]-[@b14-ijo-54-05-1511]). Extensive studies have indicated that CSCs induce drug resistance by expelling intracellular therapeutic drugs to the extracellular space through transport proteins ([@b15-ijo-54-05-1511]-[@b17-ijo-54-05-1511]). A high aldehyde dehydrogenase (ALDH) activity is another element related to drug resistance in CSCs ([@b18-ijo-54-05-1511],[@b19-ijo-54-05-1511]). Beyond EMT and CSCs, a number of studies have indicated a close association between non-coding RNAs (ncRNAs) and drug resistance in GC, a possibility that has received substantial research attention.

ncRNAs are a type of RNA that does not encode proteins, and they are associated with cell development, metastasis, invasion, proliferation and apoptosis ([@b20-ijo-54-05-1511]). ncRNAs are thought to be involved in drug resistance in human GC ([@b21-ijo-54-05-1511]). Among ncRNAs, microRNAs (miRNAs or miRs) and long non-coding RNAs (lncRNAs), two main families of ncRNAs, play a role in cancer drug resistance ([@b22-ijo-54-05-1511]). miRNAs are approximately 19-25 nucleotides in length and can bind to the 3′-untranslated region (3′-UTR) of target genes to regulate their expression ([@b23-ijo-54-05-1511]). Studies have analyzed the association between miRNAs and drug resistance in GC ([@b21-ijo-54-05-1511],[@b24-ijo-54-05-1511],[@b25-ijo-54-05-1511]). lncRNAs are \>200 nucleotides in length and are always transcribed by RNA polymerase II, and they lack opening reading frames (ORFs) ([@b26-ijo-54-05-1511],[@b27-ijo-54-05-1511]). lncRNAs exert their effects by interacting with DNA, RNA and protein ([@b28-ijo-54-05-1511]). Several studies have investigated the function of lncRNAs in drug resistance in GC ([@b21-ijo-54-05-1511],[@b28-ijo-54-05-1511],[@b29-ijo-54-05-1511]). In this review, we summarize the mechanisms underlying the role of miRNAs and lncRNAs in regulating drug resistance in GC.

2. Multi-drug resistance and single drug resistance
===================================================

Over the past decades, several chemotherapeutic regimens based on different anti-cancer drugs have improved the survival of a multitude of patients GC. However, chemotherapy in patients with GC often fails due to the development of multi-drug resistance (MDR) and single drug resistance ([@b30-ijo-54-05-1511]-[@b32-ijo-54-05-1511]). Both MDR and single drug resistance in GC are regulated by complex mechanisms, including some classic approaches ([Fig. 1](#f1-ijo-54-05-1511){ref-type="fig"}). One mechanism of MDR is the modulation of apoptosis and autophagy in cancer cells induced by anti-cancer drugs ([@b25-ijo-54-05-1511]). For example, miR-218 has been shown to inhibit drug-induced apoptosis by increasing the expression of Bcl-2-associated X protein (Bax) and decreasing the expression of B-cell lymphoma-2 (Bcl-2) ([@b33-ijo-54-05-1511]). miR-23b-3p targets autophagy-related gene 12 (*ATG12*) and high mobility group box 2 (HMGB2) to prevent autophagy and increase the sensitivity of GC cells to 5-fluorouracil (5-FU), vincristine (VCR) and cisplatin (DDP/CDDP) ([@b34-ijo-54-05-1511]). Another important mechanism leading to MDR is the induction of drug efflux in cancer cells by increasing specific energy-dependent transporters, such as P-glycoprotein 1 (P-gp; also known as ABCB1) ([@b25-ijo-54-05-1511]). For instance, miR-106a expedites the efflux of adriamycin (ADR/ADM) to promote ADR resistance in GC by targeting runt-related transcription factor 3 (RUNX3) directly ([@b35-ijo-54-05-1511]). Other mechanisms that may lead to drug resistance have been reported, including DNA damage repair, the mutation of drug targets and the modification of stem cells among others ([@b36-ijo-54-05-1511]-[@b43-ijo-54-05-1511]).

In addition to these ncRNAs that lead to MDR, there are other ncRNAs that are related to the chemosensitivity of single anti-cancer drugs in GC, including DDP, 5-FU, and VCR. Although some of these ncRNAs play roles in more than one type of drug resistance, the identification of ncRNAs related to single drug resistance is an area worth exploring to promote the development of more effective chemotherapeutic drugs for the treatment of GC.

3. Non-coding RNAs related to multi-drug resistance in gastric cancer
=====================================================================

Dysregulated miRNAs
-------------------

In recent years, several studies have focused on the association between miRNAs and MDR in GC. A number of miRNAs are involved in drug sensitivity in GC via common mechanisms such as apoptosis, the mammalian target of rapamycin (mTOR) pathway and the EMT pathway. miR-185 has been shown to be downregulated in GC and to be related to the resistance to multiple drugs such as ADR, 5-FU, oxaliplatin (L-OHP/OXA), doxorubicin (DOX) and CDDP through the regulation of zinc finger protein 139 (ZNF139) and apoptosis repressor ([@b44-ijo-54-05-1511],[@b45-ijo-54-05-1511]). miR-218 targets smoothened (SMO) directly to reverse the drug resistance of GC cells to ADM, L-OHP and 5-FU ([@b33-ijo-54-05-1511]). It has been demonstrated that miR-218 is upregulated in patients with GC undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and it targets mTOR to promote the chemosensitivity of GC cells to CDDP *in vitro* ([@b46-ijo-54-05-1511]). Zeng *et al* demonstrated that miR-145 targets the 3′-UTR of *CD44* directly to promote chemosensitivity to 5-FU and DDP in GC ([@b47-ijo-54-05-1511]). miR-101 enhances the sensitivity to DDP or VCR by regulating Annexin A2 (ANXA2) and vascular endothelial growth factor (VEGF)-C negatively to inhibit viability and promote apoptosis of GC cells ([@b48-ijo-54-05-1511],[@b49-ijo-54-05-1511]). miR-495 targets the multi-drug resistance protein 1 (*MDR1*) gene to enhance the sensitivity of GC cells to paclitaxel (PTX) and DOX ([@b50-ijo-54-05-1511]). By targeting enhancer of zeste homolog 2 (EZH2) directly, miR-126 increases the sensitivity of GC cells to VCR and ADR ([@b51-ijo-54-05-1511]). Shang *et al* demonstrated that miR-508-5p targets ABCB1 and Zinc ribbon domain-containing 1 (ZNRD1) directly to regulate the MDR of GC cells ([@b52-ijo-54-05-1511]). In addition, the upregulation of miR-27b has been shown to promote miR-508-5p expression via cyclin G1 (CCNG1) and p53 in GC cells, enhancing the sensitivity to chemotherapeutic agents, such as ADR, VCR, 5-FU and CDDP ([@b53-ijo-54-05-1511]). Other miRNAs, including miR-30a ([@b30-ijo-54-05-1511],[@b54-ijo-54-05-1511],[@b55-ijo-54-05-1511]), miR-107 ([@b56-ijo-54-05-1511]), miR-BART20-5p ([@b57-ijo-54-05-1511]), miR-23b-3p ([@b34-ijo-54-05-1511]) and miR-129-5p ([@b58-ijo-54-05-1511]) have been shown to promote chemotherapeutic sensitivity in GC, and these miRNAs and the brief mechanisms are presented in [Table I](#tI-ijo-54-05-1511){ref-type="table"}.

Numerous miRNAs have opposite functions in MDR through classical signaling pathways, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB/Akt) and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) pathways ([@b59-ijo-54-05-1511],[@b60-ijo-54-05-1511]). miR-20a is an important upregulated miRNA in GC ([@b59-ijo-54-05-1511]-[@b62-ijo-54-05-1511]). Zhou *et al* reported that miR-20a not only decreased the sensitivity of GC cells to VCR, ADR, 5-FU and CDDP by directly targeting leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), but also affected the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and PI3K/Akt signaling pathways, which are mediated by epidermal growth factor receptor (EGFR) to regulate GC cell MDR ([@b59-ijo-54-05-1511]). Other studies have indicated that miR-20a inhibits the expression of cylindromatosis (CYLD) and NFKBIB (also known as IκBβ), activating the NF-κB pathway and two downstream targets, livin and survivin, to promote GC chemoresistance to DDP ([@b60-ijo-54-05-1511],[@b61-ijo-54-05-1511]). Another study indicated that miR-20a enhanced the resistance of GC cells to docetaxel (DOC) ([@b62-ijo-54-05-1511]). miR-363 has been reported to target F-box and WD repeat domain-containing 7 (FBW7) directly to reduce the sensitivity of GC cells to the DOC + DDP + 5-FU (DCF) regimen ([@b63-ijo-54-05-1511]). miR-106a promotes ADR and DDP resistance in GC cells by expediting the efflux of ADR, targeting RUNX3 to inhibit apoptosis induced by ADR, and modulating phosphatase and tensin homologue (PTEN) and its downstream PI3K/Akt signaling pathway ([@b35-ijo-54-05-1511],[@b64-ijo-54-05-1511]). miR-20b, miR-27a and miR-181a have been shown to enhance the resistance of GC cells to epirubicin/oxaliplatin/capecitabine (EOX) by targeting hypoxia inducible factor-1 (HIF1A/HIF-1α), MDR1 and homeodomain-interacting protein kinase-2 (HIPK2) ([@b65-ijo-54-05-1511]). miR-27a, which acts as a biomarker to predict 5-FU-based chemotherapy responses in GC, induces resistance to ADR in GC cells via P-gp, cyclin D1 and p21, and it is inhibited by upstream HIF-1α to suppress MDR1/P-gp, lipoprotein receptor-related protein (LRP) and Bcl-2 to reduce L-OHP resistance ([@b66-ijo-54-05-1511]-[@b68-ijo-54-05-1511]). miR-223 negatively regulates the expression of F-box and WD repeat domain-containing 7 (FBXW7) to influence cell cycle progression in DDP-resistant cells, thereby modulating DDP resistance, and its overexpression in HER2-positive GC cells inhibits FBXW7 expression and enhances the resistance to trastuzumab (TZ) by preventing TZ-induced apoptosis ([@b69-ijo-54-05-1511],[@b70-ijo-54-05-1511]). miR-21 enhances the resistance to several drugs, such as DDP, PTX and TZ by targeting PTEN, the PI3K/Akt signaling pathway and P-gp ([@b71-ijo-54-05-1511]-[@b73-ijo-54-05-1511]). miRNAs involved in MDR in GC are summarized in [Table II](#tII-ijo-54-05-1511){ref-type="table"}.

The role of dysregulated miRNAs in MDR in GC cells is mediated by numerous regulatory mechanisms, including the ABCB1/MDR1/P-gp pathway, apoptosis induced by Bcl-2 family proteins, cell autophagy and the EMT process. By regulating these dysregulated miRNAs, the drug resistance of GC to chemotherapy may be reversed, and this may provide some novel ideas for the treatment of GC.

Dysregulated long non-coding RNAs
---------------------------------

Over the past decades, studies have indicated that lncRNAs play significant roles in the biological behaviors of GC cells, such as carcinogenesis, development, proliferation, invasion and metastasis, as well as chemosensitivity and drug resistance ([@b21-ijo-54-05-1511],[@b74-ijo-54-05-1511]). To provide new directions for the research of MDR in GC cells, in this review, we focus on the complex molecular mechanisms underlying anti-cancer drug resistance modulated by various lncRNAs ([Table III](#tIII-ijo-54-05-1511){ref-type="table"}).

Shang *et al* reported that lncRNA CASC9 downregulated the expression of MDR1 to reverse the MDR of GC cells to PTX and ADR ([@b75-ijo-54-05-1511]). Wang *et al* reported that lncRNA MRUL increased the expression of ABCB1 to enhance the sensitivity of GC cells to ADR and VCR and suppress the MDR phenotype ([@b76-ijo-54-05-1511]). Xu *et al* demonstrated that lncRNA ZFAS, whose expression was upregulated in GC cells, enhanced DDP and PTX resistance in SGC7901 cells by modulating the Wnt/β-catenin signaling pathway ([@b77-ijo-54-05-1511]). lncRNA MALAT1 competes with miR-23b-3p to promote the expression of ATG12 and enhance the resistance to VCR and DDP ([@b78-ijo-54-05-1511]). The overexpression of lncRNA UCA1, which negatively correlates with miR-27b expression, enhances drug resistance to ADR, DDP and 5-FU by inhibiting miR-27b and Bcl-2 and inducing cleaved caspase-3 ([@b79-ijo-54-05-1511]). Another study demonstrated that the downregulation of lncRNA UCA1 promoted the sensitivity of SGC7901/ADR cells to ADR by inducing cleaved Poly ADP-ribose polymerase (PARP) and inhibiting Bcl-2 ([@b80-ijo-54-05-1511]). lncRNA ANRIL is upregulated both in BGC823/DDP and BGC823/5-FU cells, and the silencing of lncRNA ANRIL reverses MDR in GC cells by targeting MDR1 and multi-drug resistance-associated protein 1 (MRP1) ([@b81-ijo-54-05-1511]).

In summary, lncRNAs modulate the MDR of GC cells through various mechanisms, such as the Wnt/β-catenin signaling pathway, the MDR1/MRP1 pathway, Bcl-2/caspase-3 induced apoptosis and by acting as competitive endogenous RNA (ceRNA). Notably, these reports suggest that the dysregulation of all lncRNAs involved in MDR in GC consists of upregulation, and no downregulated lncRNAs leading to MDR in GC cells have been identified to date, at least to the best of our knowledge.

4. Non-coding RNAs related to single drug resistance in gastric cancer
======================================================================

Cisplatin
---------

DDP/CDDP is an anti-cancer agent that can destroy the target DNA of tumor cells ([@b82-ijo-54-05-1511]). It is one of the most widely used first-line anti-cancer agents in clinical therapy, and CDDP resistance, which often occurs in GC, can result in therapeutic failure ([@b83-ijo-54-05-1511]). Chemoresistance has attracted the attention of scientists, and many complex molecular mechanisms of DDP resistance in GC cells have been elucidated to date.

miRNAs can increase the chemosensitivity of GC cells to anti-cancer drugs. For example, the overexpression of miR-125b has been shown to enhance the chemosensitivity to DDP in GC by targeting human epidermal growth factor receptor-2 (HER2) ([@b84-ijo-54-05-1511]). Wang and Ji found that miR-17-5p targeted p21 to modulate apoptosis caused by DDP in GC, and the downregulation of miR-17-5p enhanced the sensitivity of GC cells to DDP ([@b85-ijo-54-05-1511]). miR-22 upregulates the expression of the glycolytic enzyme enolase1 (*ENO1*) by targeting its 3′-UTR to attenuate the DDP resistance of GC cells ([@b86-ijo-54-05-1511]). miR-129 decreases the expression of P-gp to abate the resistance of GC cells to CDDP ([@b87-ijo-54-05-1511]). The overexpression of miR-148a-3p reduces the resistance of GC cells to CDDP by inducing mitochondrial fission and downregulating A-kinase anchoring protein 1 (AKAP1), preventing cyto-protective autophagy by decreasing Ras-related protein Rab-12 (RAB12) expression and mTOR1 activation ([@b88-ijo-54-05-1511]). AKAP1 inhibits dynamin-related protein 1 (DRP1) dephosphorylation, which is mediated by p53, to enhance CDDP resistance ([@b88-ijo-54-05-1511]). miR-320a targets a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) directly to abate the sensitivity of GC cells to CDDP ([@b89-ijo-54-05-1511]). The overexpression of miR-181a prevents the autophagy of GC cells and enhances the sensitivity of GC cells to CDDP by targeting autophagy related 5 (ATG5) ([@b90-ijo-54-05-1511]). Other miRNAs that enhance the chemosensitivity of DDP in GC include miR-203 ([@b91-ijo-54-05-1511]), miR-149 ([@b92-ijo-54-05-1511]), miR-143 ([@b93-ijo-54-05-1511]), miR-26a ([@b94-ijo-54-05-1511]), miR-1271 ([@b95-ijo-54-05-1511]) and miR-503 ([@b96-ijo-54-05-1511]). These miRNAs and a brief description of their mechanisms are presented in [Table IV](#tIV-ijo-54-05-1511){ref-type="table"}.

Certain miR NAs exert opposite effects on chemosensitivity in DDP-resistant GC cells. miR-25 has been shown to decrease the sensitivity of GC cells to cisplatin by targeting forkhead box O3a (FOXO3a) directly ([@b97-ijo-54-05-1511]). The chemoresistance of GC to DDP induced by miR-214 is reversed by exosomes, which act as nanoparticles ([@b98-ijo-54-05-1511]). A low expression of miR-99a and miR-491 enhances the sensitivity of GC cells to cisplatin by targeting calpain small subunit 1 (CAPNS1)/calpain1/calpain2/caspase-3/PARP1 signaling pathway directly ([@b83-ijo-54-05-1511]). miR-493 prevents Dickkopf-1 (DKK1) expression to enhance the CDDP resistance of GC cells ([@b99-ijo-54-05-1511]). The expression level of miR-421 in GC cells is upregulated by HIF-1α and it promotes DDP resistance through E-cadherin and caspase-3 ([@b100-ijo-54-05-1511]). miR-29b promotes cisplatin resistance in GC cells through the PI3K/Akt signaling pathway ([@b101-ijo-54-05-1511]). miR-141 overexpression inhibits the expression of Kelch-like ECH-associated protein 1 (KEAP1) and promotes the cisplatin resistance of SGC7901/DDP cells ([@b102-ijo-54-05-1511]). Other miRNAs, such as miR-132 ([@b103-ijo-54-05-1511]), miR-524-5p ([@b104-ijo-54-05-1511]), miR-34a ([@b105-ijo-54-05-1511]) and miR-200c ([@b106-ijo-54-05-1511]-[@b108-ijo-54-05-1511]) also promote resistance to DDP in GC. These miRNAs related to DDP resistance are summarized in [Table IV](#tIV-ijo-54-05-1511){ref-type="table"}.

A number of lncRNAs also modulate the chemosensitivity of GC cells to DDP. lncRNA HOTAIR inhibits the expression of miR-34a to promote DDP resistance in GC through the Wnt/β-catenin and PI3K/Akt signaling pathways ([@b109-ijo-54-05-1511]). Another study indicated that lncRNA HOTAIR functions as a ceRNA of miR-126 by inhibiting its expression and increasing vascular endothelial growth factor A (VEGFA) and phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) expression, thereby activating the PI3K/Akt/MRP1 signaling pathway ([@b110-ijo-54-05-1511]). lncRNA PVT1 may promote resistance to DDP by increasing mTOR/HIF-1α/P-gp/MRP1 expression or increasing MDR1/MRP/mTOR/HIF-1α expression ([@b111-ijo-54-05-1511],[@b112-ijo-54-05-1511]). lncRNA GHET1 enhances the resistance of GC cells to DDP by inhibiting Bax and increasing Bcl-2, MDR1 and MRP1 expression ([@b113-ijo-54-05-1511]). lncRNA BCAR4 enhances resistance to DDP by upregulating certain unknown biomarkers through the Wnt signaling pathway ([@b114-ijo-54-05-1511]). lncRNA AK022798 promotes the resistance of SGC7901/DDP and BGC823/DDP cells to DDP by upregulating MRP1 and P-gp and downregulating caspase-3 and caspase-8 ([@b115-ijo-54-05-1511]). lncRNA CASC2 decreases the resistance of GC to DDP by acting as a sponge for miR-19a ([@b116-ijo-54-05-1511]). These lncRNAs related to DDP resistance in GC are summarized in [Table IV](#tIV-ijo-54-05-1511){ref-type="table"}.

Apart from DDP, other anti-cancer drugs are used in the treatment of GC in clinical therapy, including 5-FU, ADR, VCR, OXA, DOX, PTX and molecularly-targeted drugs. These anti-cancer drugs also play significant roles in the treatment of GC. However, similar to DDP-resistance, chemoresistance to these drugs frequently occurs in the clinical treatment of GC and can lead to therapeutic failure. Improving our understanding of the mechanisms leading to chemoresistance and reversing the process is therefore critical. Below we discuss the associations between dysregulated ncRNAs and the single anti-cancer drugs mentioned above in GC.

5-Fluorouracil
--------------

The overexpression of miR-204 has been shown to enhance sensitivity to 5-FU in GC by inhibiting the EMT signaling pathway, and this effect is mediated by transforming growth factor-β (TGF-β) and by targeting TGF-β receptor 2 (TGF-βR2) directly ([@b117-ijo-54-05-1511]). miR-939 inhibits the Raf/mitogen-activated protein kinase kinase (MAP2K/MEK/MAPKK)/ERK signaling pathway to target solute carrier family 34 member 2 (SLC34A2), thereby decreasing the resistance of GC cells to 5-FU ([@b118-ijo-54-05-1511]). The overexpression of miR-31 weakens resistance to 5-FU by decreasing the expression of RhoA in GC ([@b119-ijo-54-05-1511]). miR-BART15-3p increases the chemosensitivity to 5-FU by targeting the tax1-binding protein 1 (*TAX1BP1*) gene and modulating NF-κB activity in GC cells ([@b120-ijo-54-05-1511]). The overexpression of miR-197 reverses resistance to 5-FU by targeting the *MAPK1* gene ([@b121-ijo-54-05-1511]).

However, miR-193-3p, which is upregulated in GC cells, enhances the 5-FU resistance of GC cells by targeting the *PTEN* gene directly ([@b122-ijo-54-05-1511]). Few lncRNAs related to 5-FU resistance in GC cells have been identified in recent years. For example, lncRNA LEIGC has been shown to decrease the resistance of GC cells to 5-FU by modulating the EMT pathway ([@b123-ijo-54-05-1511]).

All these ncRNAs and brief descriptions of their mechanisms of action as regards 5-FU resistance are presented in [Table V](#tV-ijo-54-05-1511){ref-type="table"}.

Adriamycin/doxorubicin
----------------------

The overexpression of miR-103/107 enhances the sensitivity of SGC7901/ADR cells to DOX by inhibiting P-gp function via the modulation of caveolin-1 (CAV-1) ([@b124-ijo-54-05-1511]). miR-520h is upregulated by DOX in GC cells and inhibits histone deacetylase 1 (HDAC1) to reverse DOX resistance in GC cells ([@b125-ijo-54-05-1511]).

In GC cells and patient tissue samples, the knockdown of miR-215p has been shown to increase PTEN and the tissue inhibitor of matrix metalloproteinases 3 (TIMP3) expression to weaken the drug resistance of GC to DOX ([@b126-ijo-54-05-1511]). miR-140 is downregulated in GC cells and downregulates the expression of SOX4 and resistance-associated factors ATP-binding cassette sub-family C member 1 (ABCC1) and ATP-binding cassette super-family G member 2 (ABCG2) to promote the resistance of GC cells to DOX ([@b127-ijo-54-05-1511]). miR-135a-5p reduces the sensitivity of BGC-823 cells to apoptosis to enhance ADR resistance by targeting activator protein (AP)-2α and Bcl-2 ([@b128-ijo-54-05-1511]). miR-19a/b induces ADR resistance by targeting PTEN directly ([@b129-ijo-54-05-1511]). It also upregulates mdr1 and P-gp to promote the efflux of ADR, and regulates Bax and Bcl-2 to inhibit ADR-induced apoptosis ([@b129-ijo-54-05-1511]).

lncRNA D63785 acts as a ceRNA of miR-422a, and prevents the suppression of myocyte enhancer factor 2D (MEF2D), which is dependent on miR-422a, inducing chemoresistance in GC ([@b130-ijo-54-05-1511]). DOX promotes the apoptosis of GC cells, and the knockdown of miR-422a increases the sensitivity of GC cells to this process to reverse drug resistance ([@b130-ijo-54-05-1511]). The expression level of lncRNA NEAT1 in SGC7901/ADR cells is upregulated, and it enhances ADR resistance by prevent apoptosis induced by ADR, although the potential target gene of NEAT1 remains unknown ([@b131-ijo-54-05-1511]).

Vincristine
-----------

miR-647 is downregulated in GC, and the overexpression of miR-647 suppresses ankyrin-B (ANK2) activation and downregulates the expression of focal adhesion kinase (FAK), matrix metalloproteinase (MMP)-2 and MMP12 to reverse VCR resistance in GC ([@b132-ijo-54-05-1511]). miR-1284 upregulates the expression of MYC and inhibits the expression of JUN and MMP12 by targeting eukaryotic initiation factor-4A (eIF4A1) to reduce the VCR resistance of GC cells ([@b133-ijo-54-05-1511]). The ectopic expression of miR-497 has been shown to inhibit Bcl-2 to enhance the sensitivity of SGC7901/VCR cells to apoptosis induced by VCR ([@b134-ijo-54-05-1511]). The overexpression of miR-181b inhibits Bcl-2 expression via the 3′-UTR to decrease the resistance of SGC7901/VCR cells to VCR ([@b135-ijo-54-05-1511]). The overexpression of miR-15b and miR-16 has been shown to prevent Bcl-2 expression to modulate VCR-induced apoptosis and decrease the resistance of SGC7901/VCR cells to VCR ([@b136-ijo-54-05-1511]).

Zhu *et al* demonstrated that the miR-200bc/429 cluster, which is downregulated in MDR SGC7901/VCR cells, increased Bcl-2 and X-linked inhibitor of apoptosis protein (XIAP) expression to decrease the sensitivity of MDR SGC7901/VCR cells to apoptosis induced by VCR ([@b137-ijo-54-05-1511]).

Oxaliplatin
-----------

The expression level of miR-135a in GC cells is upregulated and it inhibits the expression of E2F transcription factor 1 (E2F1) and the Sp1/Death-associated protein kinase 2 (DAPK2) signaling pathway to promote the resistance of GC cells to OXA ([@b138-ijo-54-05-1511]).

lncRNA BLACTA1 is upregulated in GC cells and tissues exhibiting resistance to OXA ([@b139-ijo-54-05-1511]). Furthermore, BLACTA1 targets miR-361 directly to induce the expression of the ABCB1 protein and promote the OXA resistance of GC ([@b139-ijo-54-05-1511]).

Taxanes
-------

Taxanes include classical drugs, such as PTX and DOC, as well as some novel ones, including cabazitaxel and abraxane (ABX) ([@b140-ijo-54-05-1511]). PTX and DOC, known as classical potent cytotoxic drugs, have been used in the treatment of a number of types of cancer, including GC. Wu *et al* demonstrated that miR-34c-5p was downregulated in PTX-resistant GC cells and tissues ([@b141-ijo-54-05-1511]). The overexpression of miR-34c-5p decreased microtubule-associated protein tau (MAPT) expression and enhanced the sensitivity of GC cells to PTX ([@b141-ijo-54-05-1511]). Tian *et al* reported that the overexpression of miR-361-5p modulated the expression of FOXM1 by targeting the PI3K/Akt/mTOR pathway, thereby preventing chemoresistance to DOC induced by autophagy in GC ([@b142-ijo-54-05-1511]). Cabazitaxel, a second-generation taxane that stabilizes microtubule, exhibits a broad spectrum anti-cancer activity ([@b143-ijo-54-05-1511]). ABX, a new commercial albumin that binds paclitaxel nanoparticle, can be used in cytopharmaceuticals that induce tumor suppression in ovarian, breast, lung and pancreatic cancer, among others ([@b144-ijo-54-05-1511],[@b145-ijo-54-05-1511]). However, to date, there have been no reports of cabazitaxel resistance or ABX resistance in GC, at least to the best of our knowledge. The association between ncRNAs and resistance to taxanes in GC is summarized in [Table VI](#tVI-ijo-54-05-1511){ref-type="table"}.

Molecular targeted drugs
------------------------

As one of the most rapidly developing fields, molecular targeted drugs play an important role in the treatment of GC. TZ and ramucirumab, which are first-line and second-line therapies for GC, and other specific targeted drugs, such as fibroblast growth factor receptor 2 (FGFR2) inhibitors and bromodomain and extra terminal (BET) inhibitors, are widely used in the clinical treatment of GC ([@b146-ijo-54-05-1511]). Resistance to molecular targeted drugs has been reported previously. Venturutti *et al* reported that ectopically expressed miR-16 in TZ- and lapatinib-resistant GC cells targets cyclin J (CCNJ) and far upstream element-binding protein 1 (FUBP1) to reverse TZ and lapatinib resistance in ErbB-2-positive GC cells ([@b147-ijo-54-05-1511]).

Another newly developing area, immune checkpoint molecules, has begun to attract increasing attention. Inhibiting the immune response of patients to cancer-specific antigens is a major mechanism of cancer development ([@b148-ijo-54-05-1511]). The dysregulation of immune checkpoint molecules, including cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1) and its ligand PD-L1, can activate or suppress T lymphocytes, resulting in immune tolerance and cellular immune escape ([@b149-ijo-54-05-1511],[@b150-ijo-54-05-1511]). Therefore, immune checkpoint therapy, which is based on immune checkpoint inhibitors, can regulate immune response in tumor microenvironment and kill tumor cells indirectly ([@b151-ijo-54-05-1511]). Several immune checkpoint inhibitors, including pembrolizumab, nivolumab, ipilimumab, atezolizumab, avelumab and durvalumab, which target CTLA-4, PD-1 and PD-L1, have been used in the clinical treatment of cancers such as GC, metastatic melanoma, non-small-cell lung cancer (NSCLC), head and neck squamous cell cancer, urothelial carcinoma and Hodgkin\'s lymphoma ([@b152-ijo-54-05-1511]). Pembrolizumab was the first and only immune checkpoint inhibitor to be approved by the US Food and Drug Administration (FDA) as a third-line treatment for locally advanced and metastatic GC ([@b153-ijo-54-05-1511]). However, to the best of our knowledge, there are no reports on pembrolizumab resistance in GC to date.

Immune checkpoint molecules and miRNAs are not separate. miRNAs have been reported to regulate the expression of immune checkpoint molecules to target its related pathways ([@b154-ijo-54-05-1511]). For example, miR-138 has been shown to inhibit the expression of PD-1 and CTLA-4 on the surface of both regulatory T cells, thus promoting anti-cancer immunity in glioma cell lines ([@b155-ijo-54-05-1511]). A low expression of miR-197, which correlates with a high PD-L1 expression, promotes chemoresistance in NSCLC ([@b156-ijo-54-05-1511]). Beyond miRNAs, some lncRNAs can also modulate immune checkpoint function ([@b157-ijo-54-05-1511],[@b158-ijo-54-05-1511]). However, the mechanisms how miRNAs and lncRNAs regulate the expression of immune checkpoint molecules in tumor microenvironment remain unclear.

In summary, the molecular mechanisms underlying the involvement of ncRNAs in single drug resistance in GC are varied and specific. However, certain common pathways and target genes involved in these mechanisms have been identified. A number of miRNAs can target the PTEN/PI3K/Akt, insulin-like growth factor 1 receptor (IGF1R)/insulin receptor substrate 1 (IRS1), MDR1/P-gp, Wnt/β-catenin and mTOR pathways to modulate the chemoresistance of GC cells. Some of these ncRNAs can alter the sensitivity of GC cells to apoptosis induced by anti-cancer drugs via the Bcl-2/Bax/caspase family. Targeting E-cadherin to modulate EMT in GC cells is another frequently used approach. However, the majority of lncRNAs involved in single drug resistance are upregulated in GC cells. They modulate single drug resistance through several mechanisms, including the modulation of the PI3K/Akt pathway, the Wnt/β-catenin pathway, the mTOR pathway and Bcl-2/Bax-induced apoptosis, and by acting as ceRNAs. The results described may provide novel potential biomarkers for the diagnosis and treatment of GC. These mechanisms contribute to the involvement of the large and complex network of ncRNAs in drug resistance.

5. Conclusions and future directions
====================================

Both miRNAs and lncRNAs play significant roles in modulating cancer chemosensitivity to regulate drug resistance in GC and form a complex regulating network ([Fig. 2](#f2-ijo-54-05-1511){ref-type="fig"}). The underlying molecular mechanisms include drug efflux, apoptosis dysfunction, DNA damage-induced repair, drug target modulation and proliferation triggering, among others ([@b22-ijo-54-05-1511]). These miRNAs, lncRNAs, critical genes and proteins may be useful to predict the chemosensitivity of GC cells and to establish therapeutic strategies for different patients with GC.

Changes in ncRNA expression have been confirmed to contribute to the drug resistance of GC. Probably the selective regulation of ncRNA expression can partly enhance the sensitivity of GC cell lines to chemotherapy. At present, miRNA mimics and antagonists, which can imitate and silence the activity of specific miRNA, have been demonstrated to restore or antagonize miRNA functions ([@b159-ijo-54-05-1511],[@b160-ijo-54-05-1511]). Drugs based on these molecules have not been applied widely in clinical trials, apart from Miravirsen, the first miRNA-targeted drug for the treatment of hepatitis C virus (HCV) ([@b161-ijo-54-05-1511]). Miravirsen can inhibit miR-122 to reduce the HCV RNA level by comprising a locked-nucleic acids (LNA) against miR-122 and now this drug has been examined in a phase II clinical trial ([@b162-ijo-54-05-1511]). As previously described, lncRNAs can act as ceRNAs of some specific miRNAs to modulate their expression. This procession may provide a novel direction that modified or artificial lncRNAs can be designed and transmitted into cell lines to regulate expression of targeted miRNAs, although there is no report about drugs based on this mechanism to date, at least to the best of our knowledge. Another promising clinical application of ncRNAs is acting as potential biomarkers for diagnosis and chemosensitivity in GC. When circulating in the blood as free RNAs, miRNAs are quite stable and they can be easily detected in patients\' biofluids ([@b163-ijo-54-05-1511]). Some miRNAs, including miR-223, miR-16 and miR-100, have an increased expression in serum samples of patients with GC, which is associated with clinical characteristics, such as TNM stages ([@b21-ijo-54-05-1511],[@b164-ijo-54-05-1511]). Certain other miRNAs, such as miR-363, miR-519e and miR-520d have been reported to exhibit differential expression patterns in clinical samples derived from patients who can or cannot respond to chemotherapy ([@b25-ijo-54-05-1511],[@b165-ijo-54-05-1511]). A successful prediction of treatment response can be made, which would help design an effective and individual therapy planning rather than invalid chemotherapy, which has the risk of potential severe side-effects.

Although ncRNAs provide a novel direction for research on drug resistance in GC, they have not been extensively applied in clinical settings, such as in the diagnosis and treatment of GC. Chemical modification and delivery of ncRNA regulators into tumors are two well-known limitations to the clinical application of ncRNAs ([@b24-ijo-54-05-1511],[@b166-ijo-54-05-1511]). However, we believe that additional limitations exist. The safety of ncRNAs is an important problem that must be understood. RNA interference, another technique involving RNA, has been found to be toxic in preclinical mouse models ([@b167-ijo-54-05-1511],[@b168-ijo-54-05-1511]). Whether these specific markers could maintain their function continually during clinical application, in another word, the unexpected mutations, as well as polymorphisms of ncRNAs, may be another problem worth considering. Even slight mutation at some sites may alter the expression of miRNAs and lncRNAs, and influence their macro function. Real-time PCR and next-generation sequencing remain the most effective technologies for the accurate quantitative analysis of ncRNAs ([@b22-ijo-54-05-1511]). Both technologies require precise instruments and skilled technical personnel and therefore are difficult and costly. If these limitations are overcome in the future, we believe that ncRNAs may be a novel field which can be used to reverse drug resistance and improve the prognosis of patients with GC.

In recent years, the ceRNA hypothesis has attracted increasing attention, although many of the functions of ceRNAs in tumors remain unknown, including their involvement in the drug resistance of cancer cells. Studies have indicated that lncRNAs can act as ceRNAs of miRNAs, and compete with the corresponding miRNAs for binding to targets to regulate drug resistance ([@b78-ijo-54-05-1511],[@b110-ijo-54-05-1511],[@b130-ijo-54-05-1511]). In addition, studies on the association between exosomes and drug resistance in cancer cells have been published recently. Exosomes play a role in drug resistance through different mechanisms, such as excreting anti-cancer drugs from tumor cells, interacting with oncogenic targets after competing with antibody-based anti-cancer drugs to reduce the curative effect, and contributing to transmit chemoresistance from drug-resistant cells to sensitive ones ([@b169-ijo-54-05-1511]-[@b172-ijo-54-05-1511]). For instance, Wang *et al* pointed out that drug resistance in GC was modulated by exosomes loaded with miRNA, mRNA and other ncRNAs via fusing with GC cells and modulating biological behaviors such as viability, migration, and apoptosis ([@b98-ijo-54-05-1511]). In renal cell carcinoma cells, lncARSR transmitted by exosomes acts as a ceRNA to enhance sunitinib resistance by binding to miR34/miR-449 competitively ([@b173-ijo-54-05-1511]). Another member of the ncRNA family, circular RNAs (circRNAs), has become the subject of research worldwide. circRNAs are related to carcinogenesis in breast cancer, bladder cancer, GC and colorectal cancer. circRNAs function by sponging miRNAs and regulating gene transcription and encoding proteins ([@b174-ijo-54-05-1511]). For example, circPVT1 increases the expression of ABCB1 to enhance DOX and DDP resistance in osteosarcoma cells ([@b175-ijo-54-05-1511]). Although drug resistance induced by circRNAs in GC has not been reported to date, at least to the best of our knowledge, it is reasonable to believe that drug resistance related to circRNAs and GC will be identified in the future.

These results provide new research areas and may help the design of potential therapeutic strategies with which to reverse drug resistance in different patients in the future. The mechanisms of drug resistance are complex, and more extensive and comprehensive studies are required in order to elucidate the mechanisms of anti-cancer drug resistance in GC in the future.
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![Classic mechanisms involved in drug resistance in gastric cancer. miRNAs and lncRNAs modulate drug resistance in gastric cancer through classic pathways, such as the PTEN/PI3K/Akt, IGF1R/IRS1, MDR1/P-gp, Wnt/β-catenin, MAPK/ERK, NF-κB and Bcl-2/Bax pathways, which contribute to a complex regulatory network. The arrows represent activation effect and the T symbols indicate inhibition effect. miRNAs, microRNAs; lncRNAs, long non-coding RNAs; IGF1, insulin-like growth factor 1; IGF2, insulin-like growth factor 2; IGF1R, insulin-like growth factor 1 receptor; SHC, SH2 containing protein; GRB2, growth factor receptor-bound protein 2; SOS, son of sevenless; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; HIF1α, hypoxia-inducible factor 1α; Iκκ, IκB kinase; Dsh, dishevelled; GSK3β, glycogen synthase kinase 3β; AXIN, axis inhibitor; APC, adenomatous polyposis coli; ctnn-β, β-catenin; P-gp, P-glycoprotein 1.](IJO-54-05-1511-g00){#f1-ijo-54-05-1511}

![ncRNAs related to drug resistance in gastric cancer. Many ncRNAs are related to drug resistance in gastric cancer by modulating the sensitivity of gastric cancer cells to drugs, and the molecular mechanisms contribute to a complex regulatory network. Drug resistance related to other miRNAs (oxaliplatin resistance, paclitaxel resistance, trastuzumab resistance, lapatinib resistance, epirubicin resistance, oxaliplatin resistance, capecitabine resistance), drug resistance related to lncRNAs (cisplatin resistance, adriamycin resistance, oxaliplatin resistance, 5-fluorouracil resistance, paclitaxel resistance, vincristine resistance). The arrows represent an inducing effect and the T symbols indicate a reversing effect. ncRNAs, non-coding RNAs; ADR/DOX, adriamycin/doxorubicin; 5-FU, 5-fluorouracil; MDR, multi-drug resistance; VCR, vincristine; DDP, cisplatin.](IJO-54-05-1511-g01){#f2-ijo-54-05-1511}

###### 

miRNAs which reverse multi-drug resistance in gastric cancer.

  MicroRNA        Dysregulation   Effect on drug resistance   Corresponding drugs        Pathway/target                     Refs.
  --------------- --------------- --------------------------- -------------------------- ---------------------------------- ---------------------------------------------------------------------
  miR-185         ↓               Reversing                   ADR, 5-FU, OXA; DOX, DDP   MDR1/P-gp, MRP, Bcl-2; ARC/RUNX3   ([@b44-ijo-54-05-1511],[@b45-ijo-54-05-1511])
  miR-218         ↓               Reversing                   ADR, OXA, 5-FU             SMO/P-gp/Bax/Bcl2                  ([@b33-ijo-54-05-1511],[@b46-ijo-54-05-1511])
  miR-145         ↓               Reversing                   5-FU, DDP                  *CD44*                             ([@b47-ijo-54-05-1511])
  miR-101         ↓               Reversing                   DDP, VCR                   ANXA2; VEGF-C                      ([@b48-ijo-54-05-1511],[@b49-ijo-54-05-1511])
  miR-495         ↓               Reversing                   PTX, DOX                   *MDR1*/ABCB1                       ([@b50-ijo-54-05-1511])
  miR-126         ↓               Reversing                   ADR, VCR                   EZH2                               ([@b51-ijo-54-05-1511])
  miR-508-5p      ↓               Reversing                   /                          ABCB1/ZNRD1                        ([@b52-ijo-54-05-1511])
  miR-27b         ↓               Reversing                   ADR, VCR, 5-FU, DDP        CCNG1/P53/miR-508-5p               ([@b53-ijo-54-05-1511])
  miR-30a         ↓               Reversing                   DDP, 5-FU                  EMT                                ([@b30-ijo-54-05-1511],[@b54-ijo-54-05-1511],[@b55-ijo-54-05-1511])
  miR-107         ↓               Reversing                   OXA, PTX, ADR, 5-FU        Lin28                              ([@b56-ijo-54-05-1511])
  miR-BART20-5p   ↓               Reversing                   5-FU, docetaxel            BAD                                ([@b57-ijo-54-05-1511])
  miR-23b-3p      ↓               Reversing                   5-FU, VCR, DDP             *ATG12*/HMGB2/autophagy            ([@b34-ijo-54-05-1511])
  miR-129-5p      ↓               Reversing                   VCR, ADR                   ABCB1/ABCC5/ABCG1                  ([@b58-ijo-54-05-1511])

ADR, adriamycin; 5-FU, 5-fluorouracil; OXA, oxaliplatin; DOX, doxorubicin; DDP, cisplatin; VCR, vincristine; PTX, paclitaxel; MDR1, multi- drug resistance protein 1; P-gp/ABCB1, P-glycoprotein 1; MRP, multi-drug resistance-associated protein; Bcl-2, B-cell lymphoma-2; ARC, apoptosis repressor with caspase recruitment domain; RUNX3, runt-related transcription factor 3; SMO, smoothened; Bax, Bcl-2-associated X protein; ANXA2, Annexin A2; VEGF-C, vascular endothelial growth factor C; EZH2, Enhancer of Zeste Homolog 2; ZNRD1, Zinc ribbon domain-containing 1; EMT, epithelial-mesenchymal transition; BAD, Bcl-2-associated death promoter; ATG12, autophagy-related gene 12; HMGB2, high mobility group box 2;ABCC5, multi-drug resistance-associated protein 5; ABCG1, ATP-binding cassette sub-family G member 1; /, not mentioned; ↓, downregulation.

###### 

miRNAs inducing multi-drug resistance in gastric cancer.

  MicroRNA           Dysregulation   Effect on drug resistance   Corresponding drugs              Pathway/target                                                 Refs.
  ------------------ --------------- --------------------------- -------------------------------- -------------------------------------------------------------- -----------------------------------------------
  miR-20a            ↑               Inducing                    VCR, ADR, 5-FU, DDP; docetaxel   PI3K/Akt, MAPK/ERK; CYLD/NFKBIB (IκBβ)/ NF-κB/livin/survivin   ([@b59-ijo-54-05-1511]-[@b62-ijo-54-05-1511])
  miR-363            ↑               Inducing                    DCF (docetaxel+ DDP+5-FU)        FBXW7                                                          ([@b63-ijo-54-05-1511])
  miR-106a           ↑               Inducing                    DDP, ADR                         RUNX3                                                          ([@b35-ijo-54-05-1511],[@b64-ijo-54-05-1511])
  miR-20b/27a/181a   /               Inducing                    EOX                              HIF1A/MDR1/HIPK2/hypoxia                                       ([@b65-ijo-54-05-1511])
  miR-27a            ↑               Inducing                    VCR, PTX                         P-gp, cyclin D1, p21; HIF-1α/MDR1/P-gp/LRP/Bcl-2               ([@b66-ijo-54-05-1511]-[@b68-ijo-54-05-1511])
  miR-223            ↑               Inducing                    DDP, TZ                          FBXW7/apoptosis                                                ([@b69-ijo-54-05-1511],[@b70-ijo-54-05-1511])
  miR-21             ↑               Inducing                    DDP, PTX, TZ                     PTEN, PI3K/Akt pathway; P-gp                                   ([@b71-ijo-54-05-1511]-[@b73-ijo-54-05-1511])

VCR, vincristine; ADR, Adriamycin; 5-FU, 5-fluorouracil; DDP, cisplatin; OXA, oxaliplatin; EOX, epirubicin + OXA + capecitabine; PTX, paclitaxel; TZ, trastuzumab; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; CYLD, cylindromatosis; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; FBXW7, F-box and WD repeat domain-containing 7; RUNX3, runt-related transcription factor 3; HIF1A/HIF-1α, hypoxia inducible factor-1; MDR1, multi-drug resistance protein 1; HIPK2, homeodomain-interacting protein kinase-2; LRP, lipoprotein receptor-related protein; PTEN, phosphatase and tensin homologue; /, not mentioned; ↑, upregulation.

###### 

lncRNAs involved in multi-drug resistance in gastric cancer.

  lncRNA   Expression in GC   Effect on drug resistance   Drugs            Mechanism                                Refs.
  -------- ------------------ --------------------------- ---------------- ---------------------------------------- -----------------------------------------------
  CASC9    ↑                  Reversing                   PTX; ADR         Targeting MDR1                           ([@b75-ijo-54-05-1511])
  MRUL     ↑                  Reversing                   ADR; VCR         Targeting ABCB1                          ([@b76-ijo-54-05-1511])
  ZFAS     ↑                  Inducing                    DDP; PTX         Modulating Wnt/β-catenin pathway         ([@b77-ijo-54-05-1511])
  MALAT1   ↑                  Inducing                    VCR, DDP         Targeting miR-23b-3p and ATG12           ([@b78-ijo-54-05-1511])
  UCA1     ↑                  Inducing                    ADR, DDP, 5-FU   Targeting miR-27b/Bcl-2/ caspase-3 and   ([@b79-ijo-54-05-1511],[@b80-ijo-54-05-1511])
                                                                           cleaved PARP/Bcl2/apoptosis pathway      
  ANRIL    ↑                  Inducing                    DDP; 5-FU        Targeting MDR1 and MRP1                  ([@b81-ijo-54-05-1511])

PTX, paclitaxel; ADR, adriamycin; VCR, vincristine; DDP, cisplatin; 5-FU, 5-fluorouracil; MDR1, multi-drug resistance protein 1; ABCB1, P-glycoprotein 1; ATG12, autophagy-related gene 12; Bcl-2, B-cell lymphoma-2; PARP, poly ADP-ribose polymerase; MRP1, multi-drug resistance-associated protein 1; ↑, upregulation.

###### 

ncRNAs related to cisplatin resistance in gastric cancer.

  ncRNA             Dysregulation   Effect on drug resistance   Pathway/target                                                                               Refs.
  ----------------- --------------- --------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------
  miR-125b          ↓               Reversing                   HER2                                                                                         ([@b84-ijo-54-05-1511])
  miR-17-5p         ↓               Reversing                   p21                                                                                          ([@b85-ijo-54-05-1511])
  miR-22            ↓               Reversing                   *ENO1*                                                                                       ([@b86-ijo-54-05-1511])
  miR-129           ↓               Reversing                   P-gp                                                                                         ([@b87-ijo-54-05-1511])
  miR-148a-3p       ↓               Reversing                   Mitochondrial fission/AKAP1/RAB12/mTOR                                                       ([@b88-ijo-54-05-1511])
  miR-320a          ↓               Reversing                   ADAM10                                                                                       ([@b89-ijo-54-05-1511])
  miR-181a          ↓               Reversing                   Autophagy/ATG5                                                                               ([@b90-ijo-54-05-1511])
  miR-203           ↓               Reversing                   Beiberine/bcl-w                                                                              ([@b91-ijo-54-05-1511])
  miR-149           ↓               Reversing                   FoxM1                                                                                        ([@b92-ijo-54-05-1511])
  miR-143           ↓               Reversing                   IGF1R/Bcl2                                                                                   ([@b93-ijo-54-05-1511])
  miR-26a           ↓               Reversing                   NRAS/E2F2                                                                                    ([@b94-ijo-54-05-1511])
  miR-1271          ↓               Reversing                   IGF1R/IRS1/mTOR/Bcl-2                                                                        ([@b95-ijo-54-05-1511])
  miR-503           ↓               Reversing                   IGF1R/Bcl-2                                                                                  ([@b96-ijo-54-05-1511])
  miR-25            ↑               Inducing                    FOXO3a                                                                                       ([@b97-ijo-54-05-1511])
  miR-214           ↑               Inducing                    EXO-anti-214                                                                                 ([@b98-ijo-54-05-1511])
  miR-99a           ↑               Inducing                    CAPNS1/calpain1/calpain2/caspase-3/PARP1                                                     ([@b83-ijo-54-05-1511])
  miR-491           ↑               Inducing                    CAPNS1/calpain1/calpain2/caspase-3/PARP2                                                     ([@b83-ijo-54-05-1511])
  miR-493           ↑               Inducing                    DKK1                                                                                         ([@b99-ijo-54-05-1511])
  miR-421           ↑               Inducing                    E-cadherin/caspase-3                                                                         ([@b100-ijo-54-05-1511])
  miR-29b           ↑               Inducing                    PI3K/Akt pathway                                                                             ([@b101-ijo-54-05-1511])
  miR-141           ↑               Inducing                    KEAP1                                                                                        ([@b102-ijo-54-05-1511])
  miR-132           ↓               Inducing                    SIRT1/CREB/ABCG2                                                                             ([@b103-ijo-54-05-1511])
  miR-524-5p        ↓               Inducing                    SOX9                                                                                         ([@b104-ijo-54-05-1511])
  miR-34a           ↓               Inducing                    MET                                                                                          ([@b105-ijo-54-05-1511])
  miR-200c          ↓               Inducing                    ZEB2/RhoE; E-cadherin                                                                        ([@b106-ijo-54-05-1511]-[@b108-ijo-54-05-1511])
  lncRNA HOTAIR     ↑               Inducing                    miR-34a/PI3K/Akt and Wnt/β-catenin pathway; miR-126/VEGFA/PIK3R2 and PI3K/Akt/MRP1 pathway   ([@b109-ijo-54-05-1511],[@b110-ijo-54-05-1511])
  lncRNA PVT1       ↑               Inducing                    mTOR/HIF-1α/P-glycoprotein/MRP1 and MDR1/MRP/mTOR/HIF-1α pathway                             ([@b111-ijo-54-05-1511],[@b112-ijo-54-05-1511])
  lncRNA GHET1      ↑               Inducing                    Bax/Bcl2/MDR1/MRP1                                                                           ([@b113-ijo-54-05-1511])
  lncRNA BCAR4      ↑               Inducing                    Wnt signaling pathway                                                                        ([@b114-ijo-54-05-1511])
  lncRNA AK022798   ↑               Inducing                    Notch1/MRP1/P-gp/caspase-3/caspase-8                                                         ([@b115-ijo-54-05-1511])
  lncRNA CASC2      ↓               Reversing                   miR-19a                                                                                      ([@b116-ijo-54-05-1511])

HER2, human epidermal growth factor receptor-2; ENO1, enolase1; P-gp, P-glycoprotein 1; AKAP1, a-kinase anchoring protein 1; RAB12, Ras-related protein Rab-12; mTOR, mammalian target of rapamycin; ADAM10, a disintegrin and metalloproteinase domain-containing protein 10; ATG5, autophagy related 5; FoxM1, forkhead box protein M1; IGF1R, insulin-like growth factor 1 receptor; Bcl-2, B-cell lymphoma-2; IRS1, insulin receptor substrate 1; FOXO3a, forkhead box O3a; CAPNS1, calpain small subunit 1; PARP, Poly ADP-ribose polymerase; DKK1, Dickkopf-1; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; KEAP1, Kelch-like ECH-associated protein 1; SIRT1, sirtuin 1; CREB, cAMP response element-binding protein; ABCG2, ATP-binding cassette super-family G member 2; ZEB2, zinc finger E-box binding homeobox 2; VEGFA, vascular endothelial growth factor A; PIK3R2, phosphatidylinositol 3-kinase regulatory subunit beta; MRP1, multidrug resistance-associated protein 1; MDR1, multidrug resistance protein 1; HIF-1α, hypoxia inducible factor-1; Bax, Bcl-2-associated X protein; Notch 1, Notch homolog 1; ↑, upregulation; ↓, downregulation.

###### 

ncRNAs related to 5-fluorouracil resistance in gastric cancer.

  ncRNA           Dysregulation   Effect on drug resistance   Pathway/target                                                        Refs.
  --------------- --------------- --------------------------- --------------------------------------------------------------------- --------------------------
  miR-204         ↓               Reversing                   EMT pathway/TGF-β/TGF-βR2                                             ([@b117-ijo-54-05-1511])
  miR-939         ↓               Reversing                   SLC34A2 and Raf/mitogen-activated protein kinase kinase/ERK pathway   ([@b118-ijo-54-05-1511])
  miR-31          ↓               Reversing                   RhoA                                                                  ([@b119-ijo-54-05-1511])
  miR-BART15-3p   ↓               Reversing                   *TAX1BP1*/NF-κB                                                       ([@b120-ijo-54-05-1511])
  miR-197         ↓               Reversing                   *MAPK1*                                                               ([@b121-ijo-54-05-1511])
  miR-193-3p      ↑               Inducing                    *PTEN*                                                                ([@b122-ijo-54-05-1511])
  lncRNA LEIGC    ↓               Reversing                   EMT pathway                                                           ([@b123-ijo-54-05-1511])

EMT, epithelial-mesenchymal transition; TGF-β, transforming growth factor beta; TGF-βR2, TGF beta receptor 2; SLC34A2, solute carrier family 34 member 2; ERK, extracellular signal-regulated kinase; TAX1BP1, tax1-binding protein 1; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; MAPK1, mitogen-activated protein kinase; PTEN, phosphatase and tensin homologue; ↑, upregulation; ↓, downregulation.

###### 

ncRNAs involved in taxane resistance in gastric cancer.

  Drug          NcRNA        Dysregulation   Effect on drug resistance   Target/pathway            Refs.
  ------------- ------------ --------------- --------------------------- ------------------------- --------------------------
  Paclitaxel    miR-34c-5p   ↓               Reversing                   MAPT                      ([@b141-ijo-54-05-1511])
  Docetaxel     miR-361-5p   ↓               Reversing                   Autophagy/PI3K/Akt/mTOR   ([@b142-ijo-54-05-1511])
  Cabazitaxel   /            /               /                           /                         /
  Abraxane      /            /               /                           /                         /

MAPT, microtubule-associated protein tau; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; /, not mentioned; ↑, upregulation; ↓, downregulation.

[^1]: Contributed equally
